Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-dectin-2 agonist monoclonal antibody BDC-3042

An agonistic monoclonal antibody targeting the immune-activating pattern recognition receptor (PRR) dectin-2 (C-type lectin domain family 6 member A; CLEC6A), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-dectin-2 agonist monoclonal antibody BDC-3042 targets, binds to and activates dectin-2 expressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME). This may lead to the secretion of pro-inflammatory cytokines and chemokines, repolarize TAMs into immunostimulatory macrophages, and enhance antigen processing and presentation, thereby promoting phagocytosis of tumor cells and T-cell-mediated anti-tumor immune response. Dectin-2, an activating C-type lectin receptor (CLR), is expressed by TAMs in various tumor types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-dectin-2 monoclonal antibody BDC-3042
dectin-2-targeted agonistic antibody BDC-3042
Code name:BDC 3042
BDC-3042
BDC3042
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search